These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32199724)

  • 1. Accelerating the development of innovative cellular therapy products for the treatment of cancer.
    Stewart MD; Keane A; Butterfield LH; Levine BL; Thompson B; Xu Y; Ramsborg C; Lee A; Kalos M; Koerner C; Moore T; Markovic I; Lasiter L; Ibrahim R; Bluestone J; Sigal E; Allen J
    Cytotherapy; 2020 May; 22(5):239-246. PubMed ID: 32199724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celyad's novel CAR T-cell therapy for solid malignancies.
    Lonez C; Hendlisz A; Shaza L; Aftimos P; Vouche M; Donckier V; Machiels JH; Van Den Eynde M; Canon JL; Carrasco J; Odunsi K; Sahebjam S; Rottey S; Braun N; Verma B; Gilham DE; Lehmann FF
    Curr Res Transl Med; 2018 May; 66(2):53-56. PubMed ID: 29625833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital.
    Han W; Fu X
    Sci China Life Sci; 2016 Oct; 59(10):1063-1067. PubMed ID: 26025282
    [No Abstract]   [Full Text] [Related]  

  • 4. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.
    Gardner RA; White C; Elsallab M; Farnia S; Fraint E; Grilley B; Bateman-House A; Grupp SA; Kenderian S; Locke FL; Nikiforow S; Oluwole OO; Rouce RH; Spiegel J; Shah NN; Sharma A; Komanduri K; Gill S
    Transplant Cell Ther; 2024 Aug; 30(8):776-787. PubMed ID: 38762057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
    Fogli LK; Aurigemma R; Sommers CL; Singh A; Bourcier K; Ernstoff MS;
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.
    Ammar D; Schapitz I; Luu M; Hudecek M; Meyer M; Taps T; Schröder B; Ivics Z; Sanges C; Franz P; Koehl U; Negre H; Johanna I; Awigena-Cook J
    Front Immunol; 2023; 14():1280826. PubMed ID: 38077331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
    Tesfaye M; Savoldo B
    Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic approaches using genetically modified cells].
    Anliker B; Renner M; Schweizer M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1274-80. PubMed ID: 26349563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.
    Fesnak AD; Hanley PJ; Levine BL
    Curr Hematol Malig Rep; 2017 Aug; 12(4):335-343. PubMed ID: 28762038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive T-Cell Therapy for Solid Malignancies.
    Jafferji MS; Yang JC
    Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
    Thibodeaux SR; Milone MC
    Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian network analysis of risk classification strategies in the regulation of cellular products.
    Jia G; Fu L; Wang L; Yao D; Cui Y
    Artif Intell Med; 2024 Sep; 155():102937. PubMed ID: 39137589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.